Cover Image

Predicting 10‐year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT ‐ CN trial

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Lin Zhao, Feng Tao, Zhifeng Cheng, Yibing Lu, Ming Liu, Hong Chen, Min Zhang, Yang Yang, Xiang Song, Yuzi Sun, Xiao Ma, Si Si, Hanxi Zhang, Xiaoying Li
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Diabetes, Obesity and Metabolism
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Tirzepatide and health‐related quality of life in adults with obesity or overweight: Results from the SURMOUNT ‐3 phase 3 randomized trial
by: Theresa Hunter Gibble, et al.
Published: (2025)

Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT ‐1 to ‐4 trials
by: Domenica M. Rubino, et al.
Published: (2025)

Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
by: Emily R. Hankosky, et al.
Published: (2025)

Improved health‐related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT ‐5 trial
by: Alpana P. Shukla, et al.
Published: (2025)

Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight
by: Michelle Look, et al.
Published: (2025)

Correction to “Body composition changes during weight reduction with tirzepatide in the SURMOUNT ‐1 study of adults with obesity or overweight”
Published: (2025)

Impact of eligibility for diabetes remission on response to intensive lifestyle intervention in overweight and obese people with type 2 diabetes: The Look AHEAD trial
by: Joanna Y. Gong, et al.
Published: (2025)

An internet‐based platform with a low‐calorie dietary intervention improves cardiometabolic risk factors in overweight and obese people in China: Half‐year follow‐up results of a randomized controlled trial
by: Yang Zhong, et al.
Published: (2024)

Effects of intensive treatment of Chinese women with gestational diabetes on the risk of offspring being overweight from 3 to 8 years of age
by: Jing Li, et al.
Published: (2024)

Tirzepatide in the NHS : The known unknowns of treating obesity at a national scale
by: Ashley Kieran Clift, et al.
Published: (2025)

Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
by: Hiddo J. L. Heerspink, et al.
Published: (2026)

Weight loss interventions and obesity‐associated cancers in people with type 2 diabetes and overweight/obesity: A real‐world observational study
by: Testimony Ipaye, et al.
Published: (2025)

Effects of age and disease duration on the efficacy and safety of iGlarLixi in Asian people with type 2 diabetes: A post hoc analysis of the LixiLan‐O‐AP and LixiLan‐L‐CN trials
by: Wenying Yang, et al.
Published: (2024)

Association between longitudinal changes in body composition and the risk of kidney outcomes in participants with overweight/obesity and type 2 diabetes mellitus
by: Cheng Zu, et al.
Published: (2024)

The real‐life experiences of people living with overweight and obesity: A psychosocial perspective
by: Stuart W. Flint, et al.
Published: (2025)

Effect of Tirzepatide on Health‐Related Quality of Life in Japanese Patients With Obesity Disease: Patient‐Reported Outcomes From the SURMOUNT ‐J Study
by: Hiroaki Masuzaki, et al.
Published: (2026)

Effect of semaglutide on primary prevention of diabetic kidney disease in people with type 2 diabetes: A post hoc analysis of the SUSTAIN 6 randomized controlled trial
by: Jingyu Wang, et al.
Published: (2024)

Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT ‐J trial
by: Koutaro Yokote, et al.
Published: (2025)

Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world ( STEER )
by: Lauren Wilson, et al.
Published: (2026)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
by: Jia‐Jie Wang, et al.
Published: (2024)

Trajectories of body mass index and diabetes mellitus risk among elderly Chinese adults: A 10‐year longitudinal study
by: Yan Guo, et al.
Published: (2025)

The latest evidence and guidance in lifestyle and surgical interventions to achieve weight loss in people with overweight or obesity
by: Iskandar Idris, et al.
Published: (2025)

Real‐world impact of tirzepatide on the risk of progression to type 2 diabetes and metabolic outcomes in people with obesity and pre‐diabetes
by: Scott A. Coon, et al.
Published: (2025)

Impact of sotagliflozin on glomerular hyperfiltration in people with type 1 diabetes: A post hoc analysis of the inTandem3 trial
by: Amrit Pathak, et al.
Published: (2025)

Ten‐year progression of obesity‐related complications in a population with overweight and obesity in the UK : A retrospective open cohort study
by: Jonathan Pearson‐Stuttard, et al.
Published: (2024)

Interpreting Post‐Discontinuation Trajectories After Semaglutide or Tirzepatide
by: Man Sun, et al.
Published: (2026)

Variability in HbA1c and the risk of major clinical outcomes in type 2 diabetes with chronic kidney disease: Post hoc analysis from the CREDENCE trial
by: Ying Zhu, et al.
Published: (2025)

Association between patient‐reported eating behaviours and weight change: Secondary analyses of a randomized, double‐blind trial comparing retatrutide and placebo in people with obesity or overweight
by: Chisom Kanu, et al.
Published: (2025)

Efficacy and safety of intragastric expandable oral capsules in adults with overweight or obesity: A randomized, double‐blind, placebo‐controlled trial
by: Difei Lu, et al.
Published: (2024)

Pathophysiology of type 2 diabetes: A focus on the metabolic differences among southeast Asian, Chinese and Indian populations and how this impacts treatment
by: Yuzi Cao, et al.
Published: (2025)

Obesity and overweight‐related differences in cardiometabolic risk factors in type 1 diabetes
by: Adnan S. Syed, et al.
Published: (2025)

Pioglitazone reduces serum ketone bodies in sodium‐glucose cotransporter ‐2 inhibitor‐treated non‐obese type 2 diabetes: A single‐centre, randomized, crossover trial
by: Min Yang, et al.
Published: (2024)

Visceral fat mass dynamics in a 2‐year randomized STrength versus ENdurance training trial in people with obesity
by: Stefanie Lehmann, et al.
Published: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
by: Matthew J. Armstrong, et al.
Published: (2024)

Impact of baseline characteristics on the efficacy of once‐weekly subcutaneous semaglutide among participants with type 2 diabetes : A post hoc analysis of SUSTAIN China
by: Linong Ji, et al.
Published: (2024)

Real‐world treatment satisfaction with dulaglutide, and its influencing factors, in a Chinese population with type 2 diabetes mellitus
by: Lixin Guo, et al.
Published: (2024)

Precision medicine approach to detect obese people who are at high risk of developing diabetes
by: Iskandar Idris
Published: (2024)

Effects of light‐intensity physical activity on cardiometabolic parameters in young adults with overweight and obesity: The SED ‐ ACT randomized controlled crossover trial
by: Sascha W. Hoffmann, et al.
Published: (2024)

Fasting and postprandial kidney haemodynamic effects of empagliflozin and linagliptin in mono‐ and combination therapy compared to gliclazide in overweight people with type 2 diabetes ( RACELINES ): A randomised, double‐blind trial
by: Michaël J. B. van Baar, et al.
Published: (2025)

Novel metabolic and inflammatory stratification of overweight/obesity to characterize risks of adverse outcomes: A large population‐based cohort study
by: Hang Dong, et al.
Published: (2025)